Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
Lewy body
Parkinson's disease
amyloid
cytotoxicity
fibril
motor-behavior defect
neurodegenerative disease
oligomer
protein aggregation
α-synuclein
Journal
The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R
Informations de publication
Date de publication:
05 07 2019
05 07 2019
Historique:
received:
25
01
2019
revised:
22
05
2019
pubmed:
31
5
2019
medline:
11
3
2020
entrez:
31
5
2019
Statut:
ppublish
Résumé
Parkinson's disease (PD) is a neurodegenerative disorder characterized by fibrillar neuronal inclusions composed of aggregated α-synuclein (α-syn). These inclusions are associated with behavioral and pathological PD phenotypes. One strategy for therapeutic interventions is to prevent the formation of these inclusions to halt disease progression. α-Synuclein exists in multiple structural forms, including disordered, nonamyloid oligomers, ordered amyloid oligomers, and fibrils. It is critical to understand which conformers contribute to specific PD phenotypes. Here, we utilized a mouse model to explore the pathological effects of stable β-amyloid-sheet oligomers compared with those of fibrillar α-synuclein. We biophysically characterized these species with transmission EM, atomic-force microscopy, CD spectroscopy, FTIR spectroscopy, analytical ultracentrifugation, and thioflavin T assays. We then injected these different α-synuclein forms into the mouse striatum to determine their ability to induce PD-related phenotypes. We found that β-sheet oligomers produce a small but significant loss of dopamine neurons in the substantia nigra pars compacta (SNc). Injection of small β-sheet fibril fragments, however, produced the most robust phenotypes, including reduction of striatal dopamine terminals, SNc loss of dopamine neurons, and motor-behavior defects. We conclude that although the β-sheet oligomers cause some toxicity, the potent effects of the short fibrillar fragments can be attributed to their ability to recruit monomeric α-synuclein and spread
Identifiants
pubmed: 31142553
pii: S0021-9258(20)31833-0
doi: 10.1074/jbc.RA119.007743
pmc: PMC6615698
doi:
Substances chimiques
Amyloid
0
Protein Aggregates
0
alpha-Synuclein
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10392-10406Subventions
Organisme : NINDS NIH HHS
ID : P50 NS108675
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2019 Froula et al.
Références
Biophys J. 2000 Mar;78(3):1606-19
pubmed: 10692345
Neuron. 2000 Jan;25(1):239-52
pubmed: 10707987
Nat Cell Biol. 2002 Feb;4(2):160-4
pubmed: 11813001
Alzheimer Dis Assoc Disord. 2002 Jul-Sep;16(3):191-5
pubmed: 12218651
J Biol Chem. 2003 Apr 25;278(17):15313-8
pubmed: 12586824
Science. 2003 Apr 18;300(5618):486-9
pubmed: 12702875
J Neuropathol Exp Neurol. 2003 Dec;62(12):1241-53
pubmed: 14692700
Anal Biochem. 2008 Feb 15;373(2):330-6
pubmed: 17949677
Curr Protoc Neurosci. 2004 Feb;Chapter 1:Unit 1.2
pubmed: 18428596
Biochem J. 2009 Jul 15;421(3):415-23
pubmed: 19435461
Mol Neurodegener. 2010 Dec 13;5:57
pubmed: 21144050
Front Neuroanat. 2010 Dec 27;4:147
pubmed: 21212837
Proc Natl Acad Sci U S A. 2011 Mar 8;108(10):4194-9
pubmed: 21325059
Neuron. 2011 Oct 6;72(1):57-71
pubmed: 21982369
Biochem J. 2012 May 1;443(3):719-26
pubmed: 22316405
Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):4443-8
pubmed: 22403062
J Exp Med. 2012 May 7;209(5):975-86
pubmed: 22508839
Cell. 2012 May 25;149(5):1048-59
pubmed: 22632969
Science. 2012 Nov 16;338(6109):949-53
pubmed: 23161999
Brain. 2013 Apr;136(Pt 4):1128-38
pubmed: 23466394
Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):E3138-47
pubmed: 23898162
Nat Commun. 2013;4:2575
pubmed: 24108358
Acta Neuropathol Commun. 2014 Aug 06;2:88
pubmed: 25095794
Nat Protoc. 2014 Sep;9(9):2135-46
pubmed: 25122523
Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):E4274-83
pubmed: 25246573
Cell Rep. 2015 Mar 3;10(8):1252-60
pubmed: 25732816
Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):E1994-2003
pubmed: 25855634
Biomolecules. 2015 Apr 23;5(2):617-34
pubmed: 25915624
J Clin Invest. 2015 Jul 1;125(7):2721-35
pubmed: 26075822
Nat Commun. 2015 Jun 16;6:7314
pubmed: 26076669
Neurobiol Dis. 2015 Oct;82:185-199
pubmed: 26093169
Mol Cell. 2015 Sep 3;59(5):781-93
pubmed: 26300264
EMBO J. 2015 Oct 1;34(19):2408-23
pubmed: 26323479
Proc Natl Acad Sci U S A. 2015 Sep 22;112(38):E5308-17
pubmed: 26324905
Antioxid Redox Signal. 2016 Mar 1;24(7):376-91
pubmed: 26564470
J Cell Sci. 2016 May 1;129(9):1792-801
pubmed: 26989132
Sci Transl Med. 2016 Jun 8;8(342):342ra78
pubmed: 27280685
J Biol Chem. 2016 Sep 2;291(36):18675-88
pubmed: 27382062
J Exp Med. 2016 Aug 22;213(9):1759-78
pubmed: 27503075
Acta Neuropathol Commun. 2016 Aug 08;4(1):80
pubmed: 27503460
Cell Rep. 2016 Sep 20;16(12):3373-3387
pubmed: 27653697
Science. 2016 Sep 30;353(6307):
pubmed: 27708076
Cell Rep. 2017 Jan 3;18(1):161-173
pubmed: 28052246
Neurobiol Dis. 2018 Jan;109(Pt B):201-208
pubmed: 28363800
Neurobiol Dis. 2017 Sep;105:84-98
pubmed: 28576704
J Biol Chem. 2017 Aug 11;292(32):13482-13497
pubmed: 28611062
Neurobiol Dis. 2018 Jan;109(Pt B):178-190
pubmed: 28709995
Nat Neurosci. 2017 Nov;20(11):1560-1568
pubmed: 28920936
Science. 2017 Dec 15;358(6369):1440-1443
pubmed: 29242346
J Parkinsons Dis. 2018;8(2):303-322
pubmed: 29400668
Behav Brain Res. 2018 May 2;343:41-49
pubmed: 29407413
Nature. 2018 May;557(7706):558-563
pubmed: 29743672
Handb Clin Neurol. 2018;153:321-335
pubmed: 29887143
Neurobiol Dis. 2019 Apr;124:276-288
pubmed: 30381260
Res Commun Chem Pathol Pharmacol. 1985 Dec;50(3):435-41
pubmed: 3878557
Nature. 1997 Aug 28;388(6645):839-40
pubmed: 9278044
J Comp Neurol. 1997 Nov 17;388(2):211-27
pubmed: 9368838